Compare Citius Pharmaceuticals Inc (CTXR) vs Quanta Services Inc (PWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Quanta Services Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Quanta Services Inc trades at $688.88 (market cap $103.03B). The key difference: Quanta Services Inc is far larger — about 7564.6× Citius Pharmaceuticals Inc's market cap, and Quanta Services Inc pays a 0.06% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Quanta Services Inc for 62 Days on average.
| CTXR | PWR | |
|---|---|---|
Market Cap | $13.62M | $103.03B |
Volume | 132,438 | 977,892 |
Sector | Health | Industrials |
52-Week High | $1.82 | $785.24 |
52-Week Low | $0.48 | $412.21 |
Typical Hold Time | 16 Days | 62 Days |
Enterprise Value | $3.79M | $109.13B |
Dividend Yield | — | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
PWR trades at $701.07, down 2.57% on the day, but maintains a bullish technical stance with strong support near $690. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth is robust, climbing from $17.1B in 2022 to $28.5B in 2025, though net margins remain modest at 4.03%. Analyst sentiment is overwhelmingly positive, with a consensus price target of $802.08 implying significant upside.
The outlook for PWR is favorable, driven by a record $53B backlog and exposure to AI infrastructure spending. Key risks include execution challenges on large projects and rising debt levels. With 75% of analysts rating it a Buy and strong institutional support, the stock presents a growth opportunity, but investors should monitor cash flow trends and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →
